TuHURA Biosciences, Inc./NV Logo

TuHURA Biosciences, Inc./NV

Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.

HURA | US

Overview

Corporate Details

ISIN(s):
US49720K1016
LEI:
Country:
United States of America
Address:
10500 UNIVERSITY CENTER DR., 33612 TAMPA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's core mission is to address the challenges of treatment resistance in cancer patients. Its pipeline is built upon distinct technology platforms, including the IMMUNE FX (IFX) innate immune agonist, designed to enhance the efficacy of existing and new cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TuHURA Biosciences, Inc./NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TuHURA Biosciences, Inc./NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TuHURA Biosciences, Inc./NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea
016580

Talk to a Data Expert

Have a question? We'll get back to you promptly.